

SUPPLEMENTARY DATA**Table 1**

Multivariable logistic regression model performed to create the propensity score

	OR (95%CI)	P
Age, y	0.98 (0.95-1.01)	.135
Male sex	0.83 (0.36-1.90)	.659
Health care-associated IE	0.59 (0.27-1.28)	.179
Prosthetic valve IE	2.02 (0.74-5.49)	.168
Previous IE	0.40 (0.10-1.64)	.203
COPD	2.52 (1.05-6.00)	.038
Diabetes mellitus	1.38 (0.59-3.21)	.461
Cancer	2.97 (0.90-9.83)	.074
Charlson index	0.79 (0.67-0.92)	.003
Leukocyte count	1.00 (0.99-1.00)	.435
Hemoglobin	0.92 (0.77-1.09)	.326
Platelet count	1.00 (1.00-1.00)	.009
EGFR	0.99 (0.98-1.01)	.874
Vegetation present	0.85 (0.30-2.41)	.766
New moderate or severe valve regurgitation	1.11 (0.35-3.52)	.863
Abscess	1.17 (0.52-2.66)	.706
LVEF	1.02 (0.99-1.05)	.175
<i>Staphylococcus aureus</i>	0.80 (0.38-1.71)	.572
Heart failure	2.73 (1.27-5.88)	.010
AV block	2.12 (0.69-6.53)	.189
Shock	0.66 (0.28-1.53)	.332
Embolization	1.42 (0.61-3.32)	.413
Stroke	0.34 (0.14-0.83)	.018
EuroSCORE	0.97 (0.95-0.99)	.005

AV, atrioventricular; COPD, chronic obstructive pulmonary disease; EGFR, estimated

glomerular filtration rate; IE, infective endocarditis; LVEF, left ventricular ejection fraction.

Table 2

Indications for cardiac surgery

	Overall (n = 271)	Unmatched cohort			Matched cohort (n = 132)		
		Surgery (n = 188)	SINUS-LSIE (n = 83)	P	Surgery (n = 66)	SINUS-LSIE (n = 66)	P
Severe valvular regurgitation	130 (48.0)	93 (49.5)	37 (44.6)	.458	21 (31.8)	29 (43.9)	.151
Local complication	73 (27.0)	48 (25.5)	25 (30.1)	.433	21 (31.8)	19 (28.8)	.705
Heart failure	38 (14.0)	32 (17.0)	6 (7.2)	.032	16 (24.2)	6 (9.1)	.020
Embolic event	11 (4.1)	4 (2.1)	7 (8.4)	.015	3 (4.6)	5 (7.6)	.466
Vegetation size	4 (1.5)	2 (1.1)	2 (2.4)	.397	2 (3.0)	2 (3.0)	1.000
Early prosthetic valve IE	4 (1.5)	3 (1.6)	1 (1.2)	.806	2 (3.0)	1 (1.5)	.559
Multiresistant organism	3 (1.1)	2 (1.1)	1 (1.2)	.919	1 (1.5)	1 (1.5)	1.000
Persistent bacteremia	2 (0.7)	0	2 (2.4)	.033	0	2 (3.0)	.154

IE, infective endocarditis; SINUS-LSIE, surgery-indicated not undergoing surgery patients with left-sided infective endocarditis.

Unless otherwise indicated, the data are presented as No. (%).

Table 3

Univariable and multivariable Cox regression analyses for 61-day to 3-year mortality

	Univariable Analysis		Multivariable Analysis	
	HR (95% CI)	P	HR (95%CI)	P
Age, y	1.04 (1.01-1.07)	.015		
Male sex	0.51 (0.25-1.03)	.062		
Health care-associated IE	1.27 (0.61-2.73)	.528		
Prosthetic valve IE	1.29 (0.63-2.65)	.478		
Unknown etiology	1.00 (0.30-3.27)	.994		
SINUS-LSIE	3.19 (1.53-6.62)	.002	1.89 (0.68-5.19)	.220
Previous IE	4.07 (1.56-10.62)	.004	15.54 (4.44-54.4)	< .001
Coronary artery disease	2.45 (1.12-5.36)	.024		
COPD	0.82 (0.36-1.90)	.648		
Diabetes mellitus	3.66 (1.81-7.38)	< .001	3.17 (1.13-8.90)	.028
Cancer	1.19 (0.42-3.38)	.750		
HIV	3.10 (0.74-13.0)	.121		
Charlson index	1.28 (1.16-1.42)	< .001	1.27 (1.07-1.51)	.007
Leukocyte count	1.00 (1.00-1.01)	.889		
Hemoglobin	0.79 (0.65-0.97)	.025		
Platelet count	0.99 (0.99-1.00)	.820		
EGFR	0.98 (0.97-0.99)	.005		
Vegetation present	0.72 (0.31-1.67)	.447		
New moderate or severe valve regurgitation	0.70 (0.35-1.41)	.321		
Heart failure	1.15 (0.57-2.32)	.705		
Atrioventricular block	0.92 (0.28-3.01)	.885		
Shock	2.48 (1.15-5.36)	.021		
Embolization	1.69 (0.81-3.50)	.161		
Stroke	1.61 (0.75-3.48)	.225		
<i>Staphylococcus aureus</i>	0.59 (0.25-1.37)	.222		

<i>Enterococcus</i>	2.44 (1.17-5.05)	.017		
EuroSCORE	1.02 (1.00-1.04)	.011		

CI, confidence interval; COPD, chronic obstructive pulmonary disease; EGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; HR, hazard ratio; IE, infective endocarditis; SINUS-LSIE, surgery-indicated not undergoing surgery patients with left-sided infective endocarditis.

Table 4

Baseline demographic, clinical, and microbiological characteristics of the study participants included in the long-term analysis

	Overall (n = 178)	Surgery (n = 148)	SINUS-LSIE (n = 30)	P
<i>Age, y</i>	62.6 ± 13.8	61.5 ± 13.1	68.0 ± 13.8	.017
<i>Male sex</i>	134 (75.3)	113 (76.4)	21 (70.0)	.462
<i>Health care-associated IE</i>	57 (32.0)	43 (29.1)	14 (46.7)	.059
<i>Prosthetic valve IE</i>	58 (32.6)	45 (30.4)	13 (43.3)	.168
<i>Clinical history</i>				
Previous IE	10 (5.7)	7 (4.7)	3 (10.3)	.231
Coronary artery disease	34 (21.5)	26 (19.9)	8 (29.6)	.260
COPD	43 (24.2)	35 (23.7)	8 (26.7)	.725
Diabetes mellitus	52 (29.4)	43 (29.3)	9 (30.0)	.935
Cancer	18 (10.1)	16 (10.8)	2 (6.7)	.492
HIV	4 (2.3)	3 (2.0)	1 (3.3)	.660
Charlson Index, median (IQR)	2 (1-4)	2 (1-4)	3 (2-6)	.006
<i>Laboratory tests</i>				
Leukocyte count, × 10 ⁹ /L	11.1 ± 5.0	11.3 ± 4.9	9.9 ± 5.2	.176
Hemoglobin, g/dL	10.6 ± 1.8	10.6 ± 1.9	10.5 ± 1.8	.680
Platelet count, × 10 ⁹ /L	224 ± 106	229 ± 107	203 ± 106	.241
CRP, mg/L	77 [33-127]	81 [32-123]	72 [41-128]	.926
EGFR, mL/min/1.73m ²	63.9 ± 31.5	63.9 ± 30.0	63.9 ± 38.3	.999
<i>Echocardiography</i>				
Vegetation present	146 (82.5)	121 (82.3)	25 (83.3)	.893
New moderate or severe valve regurgitation	154 (89.0)	128 (89.5)	26 (86.7)	.651
Perforation	45 (25.3)	40 (27.0)	5 (16.7)	.234
Abscess	62 (34.8)	50 (33.8)	12 (40.0)	.515
Fistula	1 (0.6)	1 (0.7)	0	1.000
Dehiscence	5 (2.8)	4 (2.7)	1 (3.3)	1.000
LVEF, %	60.9 ± 11.1	61.6 ± 10.7	57.8 ± 12.5	.109
<i>Microbiology</i>				
<i>Staphylococcus aureus</i>	56 (31.5)	47 (31.8)	9 (30.0)	.850
<i>Streptococcus</i> species	56 (31.5)	49 (33.1)	7 (23.3)	.293
<i>Enterococcus</i> species	35 (19.7)	24 (16.2)	11 (36.7)	.010
Gram-negative	4 (2.3)	4 (2.7)	0	1.000
Fungal	3 (1.7)	2 (1.4)	1 (3.3)	.427

Unknown	16 (9.0)	16 (10.8)	0 (0)	.078
<i>Complications</i>				
Heart failure	93 (55.7)	81 (58.7)	12 (41.4)	.088
Atrioventricular block	18 (10.8)	17 (12.3)	1 (3.5)	.205
Shock	26 (15.6)	24 (17.4)	2 (6.9)	.156
Stroke	37 (20.8)	28 (18.9)	9 (30.0)	.173
Embolization	95 (56.6)	76 (54.7)	19 (65.5)	.248
<i>EuroSCORE, %</i>	14 [7-29]	12 [7-285]	28 [14-46]	.001

COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; EGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; IE, infective endocarditis; LVEF, left ventricular ejection fraction; SINUS-LSIE, surgery-indicated not undergoing surgery patients with left-sided infective endocarditis.

Unless otherwise indicated, the data are presented as No. (%), mean \pm 1 standard deviation, or median [interquartile range].

Table 5Clinical characteristics of SINUS-LSIE patients with *Staphylococcus aureus* infection

	Non- <i>S. aureus</i> (n=47)	<i>S. aureus</i> (n = 36)	P
<i>Age, y</i>	66.7 ± 16.7	70.6 ± 11.9	.237
<i>Male sex</i>	35 (74.5)	25 (69.4)	.612
<i>Healthcare-associated IE</i>	17 (36.2)	25 (69.4)	.003
<i>Prosthetic valve IE</i>	16 (34.0)	17 (47.2)	.224
<i>Laboratory tests</i>			
Leukocytes, $\times 10^9/\text{L}$	13.2 ± 8.3	11.5 ± 5.1	.291
Hemoglobin, g/dL	10.4±1.8	10.5±3.7	.903
EGFR, mL/min/1.73m ²	57.1 ± 31.7	45.0 ± 34.6	.105
<i>Echocardiography</i>			
Vegetation present	42 (89.4)	27 (77.1)	.134
New moderate or severe valve regurgitation	26 (57.8)	22 (61.1)	.762
Perforation	9 (19.2)	5 (13.9)	.526
Abscess	14 (29.8)	15 (41.7)	.261
Dehiscence	2 (4.3)	1 (2.8)	.721
<i>Complications</i>			
Heart failure	24 (53.3)	20 (55.6)	.842
AV block	3 (6.7)	5 (13.9)	.279
Shock	11 (24.4)	12 (33.3)	.378
Stroke	19 (40.4)	12 (33.3)	.508
Embolization	32 (71.1)	23 (63.9)	.489
<i>EuroSCORE</i>	34 (15-51)	35 (17-55)	.541
<i>Outcome</i>			
0- to 60-day mortality	26 (55.3)	27 (75.0)	.064

AV, atrioventricular; EGFR, estimated glomerular filtration rate; IE, infective endocarditis;

SINUS-LSIE, surgery-indicated not undergoing surgery patients with left-sided infective endocarditis.

Data are presented as No. (%) and mean ± 1 SD.